Mogamulizumab Production Cost Reports

The report provides a detailed analysis essential for establishing a Mogamulizumab production plant. It encompasses all critical aspects necessary for Mogamulizumab production, including the cost of Mogamulizumab production, Mogamulizumab plant cost, Mogamulizumab production costs, and the overall Mogamulizumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Mogamulizumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Mogamulizumab is a specialised monoclonal antibody injection that targets a protein called CCR4 found on the surface of abnormal T-cells. It is effective for treating adults with relapsed or refractory forms of mycosis fungoides and Sézary syndrome. They are rare and aggressive types of cutaneous T-cell lymphoma that primarily affect the skin but can spread to lymph nodes and blood.

It binds to these cancer cells, triggering the immune system to destroy them more efficiently through processes like antibody-dependent cellular cytotoxicity. This reduces skin lesions, slower disease progression, and improves quality of life in patients facing limited alternatives for these challenging lymphomas. Its common side effects include rash, tiredness, diarrhoea, muscle and bone pain, upper respiratory infections, infusion reactions with chills or nausea, fever, low blood counts, cough, and leg swelling.

The market for Mogamulizumab is influenced by increasing cases of cutaneous T-cell lymphomas like mycosis fungoides and Sézary syndrome. The growth in ageing populations, which are more prone to blood cancers, along with environmental triggers, contributes to its market growth.

Also, better diagnostic tools spotting these rare conditions earlier, a shift toward advanced immunotherapies and monoclonal antibodies over older chemotherapy options, boost their demand. The growth in patient assistance programs and health technology assessments impacts industrial Mogamulizumab procurement. The cost-effectiveness compared to standard treatments, along with economic considerations for combination regimens, and competition from phototherapies, impacts its market dynamics.

Raw Material for Mogamulizumab Production

According to the Mogamulizumab production plant project report, the key raw materials used in the production of Mogamulizumab include Chinese Hamster Ovary (CHO) cells and serum-free and feed media.

Production Process of Mogamulizumab

The extensive Mogamulizumab production cost report consists of the following major industrial production process:

1. From CHO cells: The Mogamulizumab production starts by thawing the CHO cell bank and growing the defucosylated antibody-producing cells in serum-free medium. This takes place from small flasks through spinners and bags to large bioreactors. The culture broth is harvested via centrifugation or ultrafiltration. The purification follows with protein A chromatography to capture the antibody, a low pH holds for viral inactivation,  and ion-exchange steps (anion and cation) to remove impurities. Finally, sterile filtration of Mogamulizumab takes place before filling into single-use vials with stabilising buffer and polysorbate.

Mogamulizumab has a molecular formula of C6520H10072N1736O2020S42 and an average molecular weight of 146-149 kDa. It contains 32 cysteine residues forming 4 interchain and 12 intrachain disulfide bonds. The antibody solution appears clear to slightly opalescent and colourless. It is available in a concentration of 8.5-10.5 mg/mL in a 5 mM sodium citrate buffer at pH 4.7-5.3. It has an isoelectric point of 8.1-8.7, and an extinction coefficient of 1.4 L·g^-¹·cm^-¹ at 280 nm. The defucosylated Fc region enhances ADCC potency, while the formulation (4 mg/mL for injection with citric acid monohydrate, glycine, polysorbate 80) ensures stability as a preservative-free sterile solution.